Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trelan G-75
- Development stage
- Unknown
- Lead developer
- Shimizu Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trelan G-75 is an oral solution containing starch partial hydrolysate, equivalent to 75g of glucose, primarily used as a diagnostic agent for glucose tolerance tests in the diagnosis of diabetes. Manufactured by AY Pharma and Yoshindo, this pharmaceutical product is administered orally to assess an individual's glucose metabolism and insulin response, with post-administration blood glucose levels providing critical data for diabetes diagnosis.
- Brand names
- TRELAN-G Oral Solution
- Other names
- トレーランG液75g
Beyond the preview
Go deeper on Trelan G-75.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trelan G-75.